CEPT Inhibitors Finally Show Potential With Obicetrapib
medscape.com
news
2022-05-30 13:30:00

MILAN â€” Adding the cholesteryl ester transfer protein (CETP) inhibitor obicetrapib to high-intensity statins significantly lowers cholesterol levels and substantially increases the number of patients achieving cholesterol targets, suggest data from the ROSE trial. The latest results are something of a reversal for the CEPT inhibitor, after a series of disappointments led to many writing them off, and the original developer of obicetrapib, Amgen, discontinuing development in 2017. However, as reported by theheart.
